ES2216630T3 - Metodos de tratar la hipertension dependiente de la sal. - Google Patents
Metodos de tratar la hipertension dependiente de la sal.Info
- Publication number
- ES2216630T3 ES2216630T3 ES99968631T ES99968631T ES2216630T3 ES 2216630 T3 ES2216630 T3 ES 2216630T3 ES 99968631 T ES99968631 T ES 99968631T ES 99968631 T ES99968631 T ES 99968631T ES 2216630 T3 ES2216630 T3 ES 2216630T3
- Authority
- ES
- Spain
- Prior art keywords
- salt
- methods
- dependent hypertension
- treating
- treating dependent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010020772 Hypertension Diseases 0.000 title abstract 2
- 230000001419 dependent effect Effects 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003511 endothelial effect Effects 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000006444 vascular growth Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9969498P | 1998-09-09 | 1998-09-09 | |
| US12640699P | 1999-03-26 | 1999-03-26 | |
| US12661599P | 1999-03-27 | 1999-03-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2216630T3 true ES2216630T3 (es) | 2004-10-16 |
Family
ID=27378887
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99968631T Expired - Lifetime ES2216630T3 (es) | 1998-09-09 | 1999-09-09 | Metodos de tratar la hipertension dependiente de la sal. |
| ES99946776T Expired - Lifetime ES2211165T3 (es) | 1998-09-09 | 1999-09-09 | Uso de un factor angiogenico para el tratamiento de angiopatias microvasculares. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99946776T Expired - Lifetime ES2211165T3 (es) | 1998-09-09 | 1999-09-09 | Uso de un factor angiogenico para el tratamiento de angiopatias microvasculares. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US6352975B1 (https=) |
| EP (2) | EP1112083B1 (https=) |
| JP (2) | JP2002532382A (https=) |
| AT (2) | ATE260675T1 (https=) |
| AU (2) | AU5910599A (https=) |
| BR (2) | BR9913533A (https=) |
| CA (2) | CA2340320C (https=) |
| DE (2) | DE69912815T2 (https=) |
| DK (2) | DK1109571T3 (https=) |
| ES (2) | ES2216630T3 (https=) |
| IL (2) | IL141686A0 (https=) |
| PT (2) | PT1109571E (https=) |
| WO (2) | WO2000013702A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2216630T3 (es) * | 1998-09-09 | 2004-10-16 | Scios Inc | Metodos de tratar la hipertension dependiente de la sal. |
| US6783954B2 (en) * | 1999-03-05 | 2004-08-31 | Compugen Ltd. | VEGF nucleic acid and amino acid sequences |
| US7078382B1 (en) | 1999-11-02 | 2006-07-18 | Genentech, Inc. | Modulation of eNOS activity and therapeutic uses thereof |
| IL148674A0 (en) * | 1999-11-02 | 2002-09-12 | Genentech Inc | Modulation of enos activity and therapeutic uses thereof |
| US7129222B2 (en) * | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
| US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
| GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| US7820178B2 (en) | 2001-08-01 | 2010-10-26 | University of Brisol | VEGF isoforms and their use as anti-angiogenic, anti-vasodilatory, anti-permeability and anti-proliferative agents |
| WO2003015605A2 (en) * | 2001-08-20 | 2003-02-27 | University Of Virginia Patent Foundation | Use of s-nitrosothiol signaling to treat disordered control of breathing |
| US7981863B2 (en) * | 2001-09-19 | 2011-07-19 | Neuronova Ab | Treatment of Parkinson's disease with PDGF |
| US7795213B2 (en) | 2001-12-13 | 2010-09-14 | Posco | Methods of contacting β amyloid protein with VEGF |
| US20030171556A1 (en) * | 2001-12-13 | 2003-09-11 | Chi-Bom Chae | Beta-amyloid binding factors and inhibitors thereof |
| US7335362B2 (en) | 2002-07-19 | 2008-02-26 | Beth Israel Deaconess Medical Center | Methods of treating pre-eclampsia or eclampsia |
| JP2006068401A (ja) * | 2004-09-03 | 2006-03-16 | Kyushu Institute Of Technology | 人工血管 |
| US7893244B2 (en) * | 2005-04-12 | 2011-02-22 | Intradigm Corporation | Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases |
| JP2008537752A (ja) * | 2005-04-12 | 2008-09-25 | イントラディグム コーポレイション | がんおよび他の新血管形成疾患を処置するためのＲＮＡｉ治療用の組成物および方法 |
| EP1964568B1 (en) * | 2005-08-31 | 2014-03-26 | National University Corporation Kagawa University | Utilization of hypertension/hypercardia-preventing effect of d-allose |
| ES2600781T3 (es) | 2008-12-04 | 2017-02-10 | Curna, Inc. | Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf |
| GB0921525D0 (en) * | 2009-12-08 | 2010-01-27 | Isis Innovation | Product and method |
| AU2018244776B2 (en) | 2017-03-30 | 2023-12-14 | Wake Forest University Health Sciences | Methods of treatment for kidney disease |
| CN113418940B (zh) * | 2021-06-24 | 2023-03-14 | 电子科技大学 | 一种基于x射线示踪颗粒的检测方法及检测装置 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4456550A (en) | 1982-11-22 | 1984-06-26 | President And Fellows Of Harvard College | Vascular permeability factor |
| US5240848A (en) | 1988-11-21 | 1993-08-31 | Monsanto Company | Dna sequences encoding human vascular permeability factor having 189 amino acids |
| WO1990011084A1 (en) | 1989-03-24 | 1990-10-04 | The Regents Of The University Of California | Endothelial cell growth factor, isolation and expression |
| US5332671A (en) | 1989-05-12 | 1994-07-26 | Genetech, Inc. | Production of vascular endothelial cell growth factor and DNA encoding same |
| US5219739A (en) | 1989-07-27 | 1993-06-15 | Scios Nova Inc. | DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121 |
| US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| US5240714A (en) * | 1989-08-29 | 1993-08-31 | Rof Jose M S | Non-digoxin-like Na+, K+ -ATPase inhibitory factor |
| US5318957A (en) * | 1992-09-02 | 1994-06-07 | The United States Of America As Represented By The Department Of Health And Human Services | Method of stimulating angiogenesis |
| EP0941116B1 (en) * | 1996-11-01 | 2005-01-19 | Ark Therapeutics Limited | Use of vegf for the manufacture of a medicament for the treatment or prevention of intimal hyperplasia and delivery device |
| US6485942B1 (en) * | 1997-02-14 | 2002-11-26 | Genentech, Inc. | Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production |
| ES2216630T3 (es) * | 1998-09-09 | 2004-10-16 | Scios Inc | Metodos de tratar la hipertension dependiente de la sal. |
-
1999
- 1999-09-09 ES ES99968631T patent/ES2216630T3/es not_active Expired - Lifetime
- 1999-09-09 JP JP2000568511A patent/JP2002532382A/ja active Pending
- 1999-09-09 AT AT99968631T patent/ATE260675T1/de not_active IP Right Cessation
- 1999-09-09 JP JP2000568510A patent/JP2002524421A/ja active Pending
- 1999-09-09 IL IL14168699A patent/IL141686A0/xx unknown
- 1999-09-09 DK DK99968631T patent/DK1109571T3/da active
- 1999-09-09 CA CA002340320A patent/CA2340320C/en not_active Expired - Fee Related
- 1999-09-09 ES ES99946776T patent/ES2211165T3/es not_active Expired - Lifetime
- 1999-09-09 DE DE69912815T patent/DE69912815T2/de not_active Expired - Fee Related
- 1999-09-09 DE DE69915310T patent/DE69915310T2/de not_active Expired - Fee Related
- 1999-09-09 AU AU59105/99A patent/AU5910599A/en not_active Abandoned
- 1999-09-09 EP EP99946776A patent/EP1112083B1/en not_active Expired - Lifetime
- 1999-09-09 PT PT99968631T patent/PT1109571E/pt unknown
- 1999-09-09 CA CA002340728A patent/CA2340728C/en not_active Expired - Fee Related
- 1999-09-09 EP EP99968631A patent/EP1109571B1/en not_active Expired - Lifetime
- 1999-09-09 AT AT99946776T patent/ATE253934T1/de not_active IP Right Cessation
- 1999-09-09 BR BR9913533-7A patent/BR9913533A/pt not_active Application Discontinuation
- 1999-09-09 US US09/392,932 patent/US6352975B1/en not_active Expired - Lifetime
- 1999-09-09 BR BR9913564-7A patent/BR9913564A/pt not_active Application Discontinuation
- 1999-09-09 DK DK99946776T patent/DK1112083T3/da active
- 1999-09-09 WO PCT/US1999/020480 patent/WO2000013702A2/en not_active Ceased
- 1999-09-09 WO PCT/US1999/020481 patent/WO2000013703A2/en not_active Ceased
- 1999-09-09 PT PT99946776T patent/PT1112083E/pt unknown
- 1999-09-09 AU AU60285/99A patent/AU6028599A/en not_active Abandoned
- 1999-09-09 IL IL14168799A patent/IL141687A0/xx unknown
-
2002
- 2002-02-26 US US10/083,817 patent/US20020193288A1/en not_active Abandoned
-
2003
- 2003-12-31 US US10/749,706 patent/US20040224885A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2216630T3 (es) | Metodos de tratar la hipertension dependiente de la sal. | |
| CL2008003939A1 (es) | Uso de escitalopram o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento de ansiedad social (divisional de la solicitud 1799-00). | |
| ES2166111T3 (es) | Uso de tiagabina para el tratamiento de trastornos del sueño. | |
| AR039511A1 (es) | Agentes que regulan, inhiben, o modulan la actividad y/o la expresion del factor de crecimiento del tejido conjuntivo (ctgf) como unico medio para disminuir la presion intraocular y para tratar las retinopatias glaucomatosas/neuropatias opticas | |
| AR045179A1 (es) | Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer | |
| BR0107565A (pt) | Formas de dosagem de benzimidazol substituìdo e método de emprego das mesmas | |
| EA200101089A1 (ru) | Новый способ лечения | |
| DE122009000036I1 (de) | Verwendung von Dapoxetin, A selektiver Serotonin Aufnahme Inhibitor mit schnellem Wirkungseintritt, zur Behandlung von sexueller Disfunktion | |
| EP1072273A4 (en) | VASKULARISIERUNGSINHIBITOREN | |
| ES2250416T3 (es) | Estimulante de secreciohn de hormona de crecimiento. | |
| EE200000685A (et) | a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis | |
| DK1255569T3 (da) | Pax2 til behandling af nyresygdomme | |
| ES2184341T3 (es) | Un metodo para la prevencion y el tratamiento de la disfuncion del miocardio. | |
| AR032422A1 (es) | Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca | |
| UY26171A1 (es) | Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía | |
| EE200300129A (et) | Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine | |
| ATE460938T1 (de) | Morpholin-derivate zur verwendung als dopaminagonisten in der behandlung von u.a. sexueller dysfunktion | |
| IT1317930B1 (it) | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione | |
| ATE344662T1 (de) | Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen | |
| FR2839450B1 (fr) | Preparation medicamenteuse notamment pour le traitement des hernies discales | |
| EA200401454A1 (ru) | Новая комбинация из обратимо действующих ингибиторов протонного насоса и используемых в терапии дыхательных путей лекарственных веществ, предназначенных для лечения респираторных заболеваний | |
| DE60135675D1 (de) | Behandlung von motorischen veränderungen mit 5-hydrxoytryptamin 1a rezeptor aktivität verstärkenden wirkstoffen | |
| PT980251E (pt) | Factor de tecido para influenciar a formacao de vasos sanguineos | |
| DE69734349D1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
| ATE392213T1 (de) | Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen |